Titre :

Use of genotypic HIV DNA testing: a DELPHI-type consensus

Auteur(s) :

Andre-Garnier, Elisabeth [Auteur]
Bocket, Laurence [Auteur]
Laboratoire de virologie - ULR 3610
Bourlet, Thomas [Auteur]
Hocqueloux, Laurent [Auteur]
Lepiller, Quentin [Auteur]
Maillard, Anne [Auteur]
Reigadas, Sandrine [Auteur]
Barriere, Guillaume [Auteur]
Durand, François [Auteur]
Montes, Brigitte [Auteur]
Stefic, Karl [Auteur]
Marcelin, Anne-Geneviève [Auteur]

Titre de la revue :

Journal of Antimicrobial Chemotherapy

Nom court de la revue :

J Antimicrob Chemother

Numéro :

79

Pagination :

578–588

Éditeur :

Oxford University Press (OUP)

Date de publication :

2024-01-23

ISSN :

1460-2091

Mot(s)-clé(s) en anglais :

hiv
mutation
genotype
virology
genotype determination
hiv dna
consensus
voting

Discipline(s) HAL :

Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Microbiologie et Parasitologie/Virologie

Résumé en anglais : [en]

Objectives As many disparities in the clinical use of HIV DNA sequencing are observed, a DELPHI-type consensus was initiated in France to homogenize use, techniques and interpretation of results. Methods Based on a ...
Lire la suite >Objectives As many disparities in the clinical use of HIV DNA sequencing are observed, a DELPHI-type consensus was initiated in France to homogenize use, techniques and interpretation of results. Methods Based on a literature review and clinical experience, a steering committee (SC) of eight virologists and one infectious disease specialist formulated statements. Statements were submitted to an independent and anonymous electronic vote of virologists and HIV clinicians in France, between October 2022 and December 2022. Results The SC developed 20 statements grouped into six categories: clinical situations for the use of HIV DNA genotyping; techniques for performing HIV DNA genotyping; consideration of apolipoprotein B mRNA editing enzyme (APOBEC) mutations; genotyping results reporting; recycling of antiretrovirals; and availability of HIV DNA genotyping tests and delays. Twenty-one virologists and 47 clinicians participated in two voting rounds and 18/20 (90%) assertions reached a ‘strong’ consensus. For example, that prior genotyping on HIV DNA is useful for clinical decision-making when considering switching to some long-acting regimens or to reduce the number of antiretroviral agents in virologically suppressed patients for whom RNA data are unavailable/not exploitable/not sufficiently informative. Two statements achieved no consensus: reporting any detected viral minority population for discussion in multidisciplinary meetings (virologists), and possible risk of virological failure when using a second-generation InSTI plus lamivudine or emtricitabine regimen in patients with undetectable viral load within ≥1 year and in the presence of a documented M184V mutation within the last 5 years (clinicians). Conclusions This DELPHI-type consensus will facilitate the strengthening and harmonization of good practice when performing HIV DNA sequencing.Lire moins >

Langue :

Anglais

Comité de lecture :

Oui

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Laboratoire de virologie - ULR 3610

Date de dépôt :

2024-06-08T21:01:21Z
2024-09-27T08:36:34Z